Main Article Content
Candida spp. are emerging pathogens of hospital-acquired infections that causes invasive candidiasis, leading to human mortality and morbidity. Evolution of resistance to different groups of antifungal drugs is a major concern nowadays. Resistance mechanism in some of the antifungal drugs are formation of biofilms, alterations in drug target and lowered intracellular drug levels caused by efflux pumps. Introduction of novel strategies are necessitous to eliminate the phenomenon of drug resistance. Drug repurposing is a promising therapeutic strategy that can improve the efﬁcacy of antifungal therapy for invasive candidiasis. Antibiotics and antifungal drugs were combined against resistant Candida spp. and the in vitro antifungal synergy were analyzed by disk diffusion methods, checkerboard microbroth dilution method and time-kill curves. Synergistic effects were seen against drug-resistant strains, but drug-susceptible strains show indifferent effects in experimental studies. Profiting from the synergistic effects of combination therapy, alternative therapeutic approaches for drug resistance could be designed. This review will discuss different antifungal drugs and their mechanism, drug-resistance mechanisms and some of the antibiotic and antifungal combinations that provide novel insights in treating invasive fungal infections.
Azevedo MM, Teixeira-Santos R, Silva AP, Cruz L, Ricardo E, Pina-Vaz C et al. The effect of antibacterial and non-antibacterial compounds alone or associated with antifungals upon fungi. Frontiers in Microbiology. 2015;6(669):669.
Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. Hidden Killers: human fungal infections. Science Translational Medicine. 2012;4(165): 165rv13.
Costa-De-Oliveira S, Pina-Vaz C, Mendonça D, Rodrigues AG. A first Portuguese epidemiological survey of fungaemia in a university hospital. European Journal of Clinical Microbiology & Infectious Diseases. 2008;27(5):365-374.
Dimopoulos G, Karabinis A, Samonis G, Falagas ME. Candidemia in immune-compromised and immunocompetent critically ill patients: A prospective comparative study. European Journal of Clinical Microbiology & Infectious Diseases. 2007;26(6):377-384.
Blumberg H, Jarvis W, Soucie J, Edwards J, Patterson J, Pfaller M et al. Risk factors for Candida bloodstream infections in surgical intensive care unit patients: The NEMIS prospective multicenter study. Clinical Infectious Diseases. 2001;33(2): 177-186.
Magill SS, Wilson LE, Thompson DL, Ray SM, Nadle J, Lynfie,ld R et al. Reduction in the Prevalence of Healthcare-Associated Infections in U.S. Acute Care Hospitals, 2015 vs 2011. Open Forum Infectious Diseases. 2017;4(1):S49.
Benedict K, Roy M, Kabbani S, Anderson EJ, Farley MM, Harb S, et al. Neonatal and Pediatric Candidemia: Results from Population-Based Active Laboratory Surveillance in Four US Locations, 2009–2015. Journal of the Pediatric Infectious Diseases Society. 2018;7(3):e78-e85.
Cleveland AA, Farley MM, Harrison LH, Stein B, Hollick R, Lockhart SR et al. Changes in Incidence and Antifungal Drug Resistance in Candidemia: Results from Population-Based Laboratory Surveillance in Atlanta and Baltimore, 2008-2011. Clinical Infectious Diseases. 2012;55(10): 1352-1361.
CDC. Centers for Disease Control and Prevention. Fungal Diseases (Invasive Candidiasis Statistics); 2018.
Toda M, Williams SR, Berkow EL, Farley MM, Harrison LH, Bonner L, et al. Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016. MMWR. Surveillance Summaries. 2019;68(8):1-15.
Lockhart SR, Iqbal N, Cleveland AA, Farley MM, Harrison LH, Bolden CB et al. Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. Cities from 2008 to 2011. Journal of Clinical Microbiology. 2012;50(11):3435-3442.
Vallabhaneni S, Westercamp M, Cleveland A, Farley MM, Harrison L, Schaffner W, et al. Emergence of echinocandin and multi-drug resistant Candida glabrata Bloodstream Infection: Data from a Large Multi-site Population-Based Candidemia Surveillance Program. Open Forum Infectious Diseases. 2014;1(1):S383.
Costa-De-Oliveira S, Rodrigues AG. Candida albicans antifungal resistance and tolerance in bloodstream infections: The Triad Yeast-Host-Antifungal. Micro-organisms. 2020;8(2):154.
Peman J, Canton E, Espinel-Ingroff A. Antifungal drug resistance mechanisms. Expert Review of Anti-infective Therapy. 2009;7(4):453-460.
Sokol-Anderson ML, Brajtburg J, Medoff G. Amphotericin B-induced oxidative damage and killing of Candida albicans. Journal of Infectious Diseases. 1986; 154(1):76-83.
Kelly S, Lamb D, Kelly D, Manning N, Loeffler J, Hebart H et al. Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol Δ5,6-desaturation. FEBS Letters. 1997; 400(1):80-82.
Arendrup M. Update on antifungal resistance in Aspergillus and Candida. Clinical Microbiology and Infection. 2014; 20(6):42-48.
Morschhauser J, Barker KS, Liu TT, BlaB-Warmuth J, Homayouni R, Rogers PD. The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathogens. 2007;3(11): e164.
Park S, Kelly R, Kahn JN, Robles J, Hsu M, Register E, et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrobial Agents and Chemotherapy. 2005;49(8):3264-3273.
Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resistance Updates. 2007;10(3):121-130.
Garcia-Effron G, Park S, Perlin DS. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: Implications for Interpretive Breakpoints. Antimicrobial Agents and Chemotherapy. 2008;53(1): 112-122.
Akins RA. An update on antifungal targets and mechanisms of resistance in Candida albicans. Medical Mycology. 2005;43(4): 285-318.
Lu M, Yu C, Cui X, Shi J, Yuan L, Sun S. Gentamicin synergises with azoles against drug-resistant Candida albicans. International Journal of Antimicrobial Agents. 2018;51(1):107-114.
Zhou Y, Wang G, Li Y, Liu Y, Song Y, Zheng W et al. In vitro Interactions between aspirin and amphotericin B against planktonic cells and biofilm cells of Candida albicans and C. parapsilosis. Antimicrobial Agents and Chemotherapy. 2012;56(6):3250-3260.
Stepanovic S, Vukovic D, Jesic M, Ranin L. Influence of acetylsalicylic acid (aspirin) on biofilm production by Candida Species. Journal of Chemotherapy. 2004;16(2):134-138.
Sun S, Li Y, Guo Q, Shi C, Yu J, Ma L. In vitro interactions between Tacrolimus and Azoles against Candida albicans determined by different methods. Antimicrobial Agents and Chemotherapy. 2007;52(2):409-417.
Maesaki S, Marichal P, Hossain MA, Sanglard D, Bossche HV, Kohno S. Synergic effects of tacrolimus and azole antifungal agents against azole-resistant Candida albicans strains. Journal of Antimicrobial Chemotherapy. 1998;42(6): 747-753.
Shi W, Chen Z, Chen X, Cao L, Liu P, Sun S. The combination of minocycline and fluconazole causes synergistic growth inhibition against Candida albicans: An in vitro interaction of antifungal and antibacterial agents. FEMS Yeast Research. 2010;10(7):885-893.
Shrestha SK, Grilley M, Anderson T, Dhiman C, Oblad J, Chang CT et al. In vitro antifungal synergy between amphiphilic aminoglycoside K20 and azoles against Candida species and Cryptococcus neoformans. Medical Mycology. 2015;53(8):837-844.
Shrestha SK, Fosso MY, Garneau-Tsodikova S. A combination approach to treating fungal infections. Scientific Reports. 2015;5(1):17070.
Gao Y, Zhang C, Lu C, Liu P, Li Y, Li H et al. Synergistic effect of doxycycline and fluconazole against Candida albicans biofilms and the impact of calcium channel blockers. FEMS Yeast Research. 2013; 13(5):453–462
Gao Y, Li H, Liu S, Zhang X, Sun S. Synergistic effect of fluconazole and doxycycline against Candida albicans biofilms resulting from calcium fluctuation and downregulation of fluconazole-inducible efflux pump gene overexpression. Journal of Medical Microbiology. 2014;63(7):956-961.
Lu M, Yang X, Yu C, Gong Y, Yuan L, Hao L et al. Linezolid in Combination with azoles induced synergistic effects against Candida albicans and protected Galleria mellonella against experimental Candidiasis. Frontiers in Microbiology. 2019;9:3142.
Liu X, Li T, Wang D, Yang Y, Sun W, Liu J et al. Synergistic antifungal effect of fluconazole combined with licofelone against resistant Candida albicans. Frontiers in Microbiology. 2017;8:2101.
Gu W, Guo D, Zhang L, Xu D, Sun S. The synergistic effect of azoles and fluoxetine against resistant Candida albicans strains is attributed to attenuating fungal virulence. Antimicrobial Agents and Chemotherapy. 2016;60(10):6179-6188.
Shinde RB, Chauhan NM, Raut JS, Karuppayil SM. Sensitization of Candida albicans biofilms to various antifungal drugs by cyclosporine A. Annals of Clinical Microbiology and Antimicrobials. 2012; 11(1):27.
Jia W, Zhang H, Li C, Li G, Liu X, Wei J. The calcineurin inhibitor cyclosporine A synergistically enhances the susceptibility of Candida albicans biofilms to fluconazole by multiple mechanisms. BMC Microbiology. 2016;16(1):113.
Zhang M, Yan H, Lu M, Wang D, Sun S. Antifungal activity of ribavirin used alone or in combination with fluconazole against Candida albicans is mediated by reduced virulence. International Journal of Antimicrobial Agents. 2020;55(1):105804.
Li Y, Jiao P, Li Y, Gong Y, Chen X, Sun S. The Synergistic antifungal effect and potential mechanism of d-penicillamine combined with fluconazole against Candida albicans. Frontiers in Microbiology. 2019;10:2853.
Gong Y, Liu W, Huang X, Hao L, Li Y, Sun S. Antifungal activity and potential mechanism of n-butylphthalide alone and in combination with fluconazole against Candida albicans. Frontiers in Microbiology. 2019;10:1461.
Liu Y, Ren H, Wang D, Zhang M, Sun S, Zhao Y. The synergistic antifungal effects of gypenosides combined with fluconazole against resistant Candida albicans via inhibiting the drug efflux and biofilm formation. Biomedicine & Pharmaco-therapy. 2020;130:110580.